This Medical Crossfire® will offer a lively case-based panel discussion covering the latest developments affecting the care of patients with prostate cancer across the disease spectrum. This program will feature a moderated discussion, covering advances in localized and metastatic prostate cancer in both hormone-sensitive and castrate-resistant disease. By focusing on the latest data in the context of clinical scenarios, the expert faculty will help you apply current and emerging treatment options to the care of your patients.

1. Describe emerging therapeutic options in prostate cancer across multiple patient populations and lines of care;
2. Integrate novel clinical evidence into clinical practice to optimize the clinical outcome of patients with prostate cancer;
3. Optimize treatment sequences using novel agents for the treatment of patients with prostate cancer;
4. Define strategies to proactively identify and mitigate adverse events associated with different prostate cancer treatment options.

There are no fees for participating in and receiving CME credit for this online activity. 

This activity can be accessed by clicking here.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The University of Cincinnati and Physicians' Education Resource are both accredited by the ACCME to provide continuing medical education for physicians, and have collaborated to design and execute this enduring material.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

The staff of University of Cincinnati and Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC or The University of Cincinnati, or any of the companies that provided commercial support for this activity.

This activity is supported by educational grants from AstraZeneca; Genomic Health, Inc.; Merck & Co., Inc. and Sanofi Genzyme.